Amgen, Inc. (AMGN) Stake Lessened by Citizens Financial Group Inc RI

Citizens Financial Group Inc RI lowered its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.4% during the third quarter, HoldingsChannel.com reports. The fund owned 68,355 shares of the medical research company’s stock after selling 945 shares during the quarter. Amgen makes up 1.1% of Citizens Financial Group Inc RI’s holdings, making the stock its 24th largest holding. Citizens Financial Group Inc RI’s holdings in Amgen were worth $14,169,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in the company. LSV Asset Management grew its position in Amgen by 3.2% during the second quarter. LSV Asset Management now owns 4,157,649 shares of the medical research company’s stock valued at $767,460,000 after purchasing an additional 128,865 shares in the last quarter. Schwab Charles Investment Management Inc. grew its position in Amgen by 2.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 3,207,242 shares of the medical research company’s stock valued at $592,025,000 after purchasing an additional 72,205 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Amgen by 17.0% during the second quarter. Dimensional Fund Advisors LP now owns 2,365,045 shares of the medical research company’s stock valued at $436,551,000 after purchasing an additional 343,690 shares in the last quarter. Bank of Montreal Can grew its position in Amgen by 13.4% during the third quarter. Bank of Montreal Can now owns 2,328,857 shares of the medical research company’s stock valued at $482,749,000 after purchasing an additional 275,469 shares in the last quarter. Finally, Swiss National Bank grew its position in Amgen by 3.2% during the second quarter. Swiss National Bank now owns 2,227,926 shares of the medical research company’s stock valued at $411,253,000 after purchasing an additional 69,500 shares in the last quarter. Institutional investors and hedge funds own 82.37% of the company’s stock.

AMGN stock opened at $193.16 on Friday. The company has a quick ratio of 2.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.05. The company has a market capitalization of $124.91 billion, a price-to-earnings ratio of 14.12, a price-to-earnings-growth ratio of 2.04 and a beta of 1.37. Amgen, Inc. has a 12 month low of $163.31 and a 12 month high of $210.19.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, October 30th. The medical research company reported $3.69 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.45 by $0.24. The company had revenue of $5.90 billion during the quarter, compared to the consensus estimate of $5.78 billion. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.27 earnings per share. On average, equities research analysts predict that Amgen, Inc. will post 14.24 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 7th. Shareholders of record on Friday, November 16th will be given a $1.32 dividend. This represents a $5.28 annualized dividend and a yield of 2.73%. The ex-dividend date of this dividend is Thursday, November 15th. Amgen’s dividend payout ratio is 41.97%.

A number of brokerages recently commented on AMGN. Cann reaffirmed a “buy” rating and set a $224.00 price objective on shares of Amgen in a research report on Monday, October 1st. Jefferies Financial Group reaffirmed a “buy” rating and set a $220.00 price objective on shares of Amgen in a research report on Monday, October 1st. Oppenheimer reaffirmed a “buy” rating and set a $224.00 price objective on shares of Amgen in a research report on Tuesday, October 2nd. Royal Bank of Canada set a $193.00 price objective on shares of Amgen and gave the company a “neutral” rating in a research report on Friday, September 28th. Finally, Zacks Investment Research raised shares of Amgen from a “hold” rating to a “buy” rating and set a $234.00 price objective on the stock in a research report on Monday, October 1st. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $204.55.

TRADEMARK VIOLATION NOTICE: “Amgen, Inc. (AMGN) Stake Lessened by Citizens Financial Group Inc RI” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/11/11/amgen-inc-amgn-stake-lessened-by-citizens-financial-group-inc-ri.html.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Further Reading: Marijuana Stocks

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply